Lot of Indonesians have Diabetes, page-6

Provide some evidence to your opinion just for once, rather than being your usual obnoxious self to others as you are again above. The point was obvious, and cited with evidence, unlike your opinion; the prevalence of diabetes (and accordingly DFU's) in Indonesia and the public authority's formal policy on that, and engagement with Recce for that purpose, that actually involved both the Indonesian and Australian Government:

"This is a historically significant bilateral initiative supported by the Australian and Indonesian Governments. In a meeting together with Senior Executives from Recce and Etana, Her Excellency Penny Williams PSM, the Australian Ambassador to Indonesia, the Indonesian Minister of Health, Mr. Budi Sadikin, and the Head of the National Research and Innovation Agency (BRIN), all were in full support of this initiative." (Feb 2024)

Phase II primary and secondary outcome in-vivo trial success;
KOL endorsement (Professors in the infectious field);
Australian Human Resource Ethics investigators;
WHO antimicrobial recognition; FDA Qualified Disease Product recognition;
FDA Fast Track Designation;
TGA Special Access Scheme qualification;
Various in-vitro studies;
Etc, etc.

But lets ignore all that evidence as Rykster has an opinion, devoid of evidence, but an opinion that R327G does not work on DFU's....in fact contrary to all of the above evidence/experts.

Or lets instead see you opinion for what it is, as countless of your posts will show, you do not judge the strategy remotely on its evidential merit, but purely from emotional and ignorant/misleading spite:



As the fourth largest populous country in the world Indonesia does in fact matter, and I am sure the hundreds of thousands of Indonesian DFU amputees would beg to differ with your callous dismissal.

"Anyone who thinks that anything that is happening in Indonesia is going to somehow be the making of this company is either very naive, or deluded. Any accreditation gained there is all but worthless - and even if the Indonesians allow its use (no one else will), where's the market? Sure. there may be plenty of need, but a company needs to charge big bucks for a curative medication, because you only get to sell 1 course per customer. So what are they going to charge for that - $50k a shot ? I think not." Rykster Feb 2025

The usual ignorant dismissal of a universal healthcare in Indonesia that, oh I don't know, organisations like the WHO recognise, but you don't. And onl

"It matters squat how many potential customers you have, if those customers cannot afford to buy your product. Alternatively, it matters squat how many sales you make, if those sales do not provide you with an adequate profit margin. Of the millions of suffers you refer to, most in Indonesia will fall into that demographic." Ryster Feb 2025

And on and on you go, ignorantly dismissing/denying the universal healthcare in Indonesia covering over 90% of the population in Indonesia and of course completely/ignorantly ignoring Indonesia's very relevant PROLANIS programme on hypertension and diabetes and very clear cost intervention as I outlined/evidenced above and which you of course ignore in your dismissals of Indonesian's in being unable to afford R327G.

And then there are the lies/denial - no way you don't of RCE's fast track designation by the FDA, I and others have flagged it so many times to you:



Again, completely untrue, the FDA has in fact granted RCE fast track designation under the Generating Antibiotic Initiatives Now (GAIN) Act (and the designation by the FDA also awards 10 years of market exclusivity post-approval). You clearly despise RCE and you deny or lie about the its business progression time and time again, as well illustrated (FDA fast track designation awarded March 24, nearly a year prior to this clearly misleading post for example).

No @zecs I have not convinced myself of the Indonesian strategy. Simple rational analysis of the evidence has. And again, for the record, I don't particularly like the CEO myself, but put personal opinion aside and look at the overall investment evidence.